Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study. (August 2019) - Stein, E.; Toth, P.; Butcher, M.B.; Kereiakes, D.; Magnu, P.; Bays, H.; Zhou, R.; Turner, T.A.